147 related articles for article (PubMed ID: 37805108)
1. Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?
Ge M; Zhu Y; Wei M; Piao H; He M
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188996. PubMed ID: 37805108
[TBL] [Abstract][Full Text] [Related]
2. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract][Full Text] [Related]
3. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
Taylor TE; Furnari FB; Cavenee WK
Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382
[TBL] [Abstract][Full Text] [Related]
4. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
5. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288
[TBL] [Abstract][Full Text] [Related]
6. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.
Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R
J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294
[TBL] [Abstract][Full Text] [Related]
7. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.
Lo HW
Curr Mol Pharmacol; 2010 Jan; 3(1):37-52. PubMed ID: 20030624
[TBL] [Abstract][Full Text] [Related]
8. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
9. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
[TBL] [Abstract][Full Text] [Related]
10. EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.
Li L; Huang Y; Gao Y; Shi T; Xu Y; Li H; Hyytiäinen M; Keski-Oja J; Jiang Q; Hu Y; Du Z
BMC Cancer; 2018 Dec; 18(1):1215. PubMed ID: 30514230
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib: early clinical development in brain cancer.
Addeo R; Zappavigna S; Parlato C; Caraglia M
Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
[TBL] [Abstract][Full Text] [Related]
12. Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.
Pinheiro KV; Thomaz A; Souza BK; Metcalfe VA; Freire NH; Brunetto AT; de Farias CB; Jaeger M; Bambini V; Smith CGS; Shaw L; Roesler R
Mol Biol Rep; 2020 Sep; 47(9):6817-6828. PubMed ID: 32862352
[TBL] [Abstract][Full Text] [Related]
13. EGFR, the Lazarus target for precision oncology in glioblastoma.
Lin B; Ziebro J; Smithberger E; Skinner KR; Zhao E; Cloughesy TF; Binder ZA; O'Rourke DM; Nathanson DA; Furnari FB; Miller CR
Neuro Oncol; 2022 Dec; 24(12):2035-2062. PubMed ID: 36125064
[TBL] [Abstract][Full Text] [Related]
14. Exploring ncRNA-mediated regulation of EGFR signalling in glioblastoma: From mechanisms to therapeutics.
Thapa R; Afzal M; Goyal A; Gupta G; Bhat AA; Almalki WH; Kazmi I; Alzarea SI; Shahwan M; Kukreti N; Ali H; Dureja H; Kumar P; Singh TG; Kuppusamy G; Singh SK; Dua K
Life Sci; 2024 May; 345():122613. PubMed ID: 38582393
[TBL] [Abstract][Full Text] [Related]
15. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of EGFR Resistance in Glioblastoma.
Pan PC; Magge RS
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187135
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY
J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958
[TBL] [Abstract][Full Text] [Related]
18. Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma.
Liu F; Mischel PS
Wiley Interdiscip Rev Syst Biol Med; 2018 Jan; 10(1):. PubMed ID: 28892308
[TBL] [Abstract][Full Text] [Related]
19. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs involved in the EGFR pathway in glioblastoma.
Xu B; Mei J; Ji W; Huo Z; Bian Z; Jiao J; Li X; Sun J; Shao J
Biomed Pharmacother; 2021 Feb; 134():111115. PubMed ID: 33341046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]